Gregg W. Stone, MD, FACC, FSCAI

Original Contribution

The Relative Effects of Abciximab and Tirofiban on Platelet Inhibition and C-Reactive Protein during Coronary Intervention

01/07/2010

Edward M. Kreps , MD;

Martin B. Leon , MD;

Alexandra J. Lansky , MD;

George D. Dangas , MD, PhD;

Adam J. Saltzman , MD;

Roxana Mehran , MD;

W. Craig Hooper , PhD;

Jeffrey W. Moses , MD;

Giora Weisz , MD;

Michael B. Collins , MD;

Gregg W. Stone , MD, FACC, FSCAI;

ABSTRACT: Background. We sought to compare the efficacy of tirofiban and abciximab on platelet inhibition as well as their effects of platelet inhibition on C-reactive protein levels during percutaneous coronary intervention (PCI). Methods....

ABSTRACT: Background. We sought...

01/07/2010

Journal of Invasive Cardiology

Original Contribution

Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY Trial

06/15/2015

Ke Xu , PhD;

Martial Hamon , MD, FESC;

Yanai Ben-Gal , MD;

E. Magnus Ohman , MD;

Gregg W. Stone , MD, FACC, FSCAI;

Roxana Mehran , MD;

Philippe Généreux , MD;

Sorin J. Brener , MD;

A. Michael Lincoff , MD;

George D. Dangas , MD, PhD;

Marco G. Mennuni , MD;

Frederick Feit , MD;

This study compares the outcomes of acute coronary syndrome patients with proximal LAD culprit lesions receiving PCI vs CABG, and found that an initial revascularization strategy of PCI compared with CABG yielded similar 1-year death, MI, and...

This study compares the outcomes...

06/15/2015

Journal of Invasive Cardiology

TAXUS Clinical Trials: TCT Recap

06/19/2008

Gregg W. Stone , MD, FACC, FSCAI;

Dr. Stone, at the recent TCT Conference, findings were presented on a variety of TAXUS Clinical Trials. What trials did you report on, and what were some of the overall findings? At TCT my colleagues and I delivered extensive long-term TAXUS...

Dr. Stone, at the recent TCT...

06/19/2008

Cath Lab Digest

clinical trial update

COAPT at 5 Years: MitraClip Benefits Persist

07/30/2023

Gregg W. Stone , MD, FACC, FSCAI;

The COAPT trial found that the success rate of the MitraClip TEER procedure was high, on the order of around 97%, and it was successful at reducing mitral regurgitation.

The COAPT trial found that the...

07/30/2023

Cath Lab Digest

Original Contribution

Multicenter International Registry of Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention with Everolimus-Eluting Stents

06/29/2012

Imad Sheiban , MD;

Si-Hyuck Kang , MD;

Ehtisham Mahmud , MD;

Gregg W. Stone , MD, FACC, FSCAI;

Khalid Bin Thani , MD;

Hyo-Soo Kim , MD, PhD;

Michael S. Lee , MD, DPM, FACFAS, FACC, FSCAI;

Jang-Hyun Cho , MD;

Dong-Kyu Jin , MD;

Kyle Gillis , BS ;

Hyeon-Cheol Gwon , MD;

In-Ho Chae , MD;

Richard K. Cheng , MD, MS;

Joseph Aragon , MD;

Abstract: Objective. The aim of this study was to assess the clinical outcomes of percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES) for the treatment of unprotected left main coronary artery (ULMCA) disease....

Abstract: Objective. The aim of...

06/29/2012

Journal of Invasive Cardiology

Impact of Gender on the Incidence and Outcome of Contrast-Induced Nephropathy After Percutaneous Coronary Intervention

08/01/2008

Ioannis Iakovou , MD;

George D. Dangas , MD, PhD;

Gregg W. Stone , MD, FACC, FSCAI;

Roxana Mehran , MD;

Gary S. Mintz , MD;

Lowell F. Satler , MD;

Kenneth M. Kent , MD, PhD;

Augusto D. Pichard , MD, FACC, FSCAI;

Martin B. Leon , MD;

Martin Fahy , MSc;

Alexandra J. Lansky , MD;

Dale T. Ashby , MBBS, PhD;

Contrast-induced nephropathy (CIN) may occur after percutaneous coronary interventions (PCI), particularly in patients with baseline chronic renal failure (CRF) and diabetes mellitus.1–3 We have reported on the adverse impact of CIN post-PCI...

Contrast-induced nephropathy...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

The Association Between the Extent of Coronary Artery Disease and Major Bleeding Events After Percutaneous Coronary Intervention: From the ACUITY Trial

03/31/2015

Gregg W. Stone , MD, FACC, FSCAI;

Adriano Caixeta , MD, PhD;

Roxana Mehran , MD;

Mahesh V. Madhavan , MD;

Ajay J. Kirtane , MD, SM;

Ke Xu , PhD;

Thomas C. McAndrew , PhD, MS;

Tullio Palmerini , MD;

Dominic P. Francese , MPH;

The relationship between the extent of coronary artery disease (CAD) and bleeding after PCI remains understudied. This study sought to evaluate the relation between the extent of CAD and bleeding risk in patients undergoing PCI for non-ST...

The relationship between the...

03/31/2015

Journal of Invasive Cardiology

SPIRIT III: Comparison of the Xience V Everolimus-Eluting Coronary Stent System with the Taxus Paclitaxel-Eluting Coronary Stent

06/19/2008

Gregg W. Stone , MD, FACC, FSCAI;

The purpose of the Xience V stent was to try and put together a best-in-class drug, enhanced durable polymer and optimized metallic stent backbone. The drug that was used was everolimus, very similar to sirolimus, which is known to have very...

The purpose of the Xience V...

06/19/2008

Cath Lab Digest

Clinical Editor's Corner

Should We Do Elective Cardiac Catheterizations on the Weekends?

03/02/2022

Samuel M. Butman , MD;

Morton J. Kern , MD, MSCAI, FACC, FAHA;

Chet Rihal ;

Jeffrey W. Moses , MD;

Steven R. Bailey , MD;

Gurpreet S. Sandhu , MD, PhD;

Srihari S. Naidu , MD;

Frederick G.P. Welt , MD;

Kirk N. Garrett ;

Barry F. Uretsky , MD;

Lloyd W. Klein , MD;

Carl L. Tommaso , MD;

Gregg W. Stone , MD, FACC, FSCAI;

Richard Chazal , MD;

Duane S. Pinto , MD, MPH;

Rajiv Gulati , MD, PhD;

James C. Blankenship , MD;

David G. Rizik , MD, FACC, FSCAI;

Bonnie H. Weiner , MD, MBA, FSCAI, FACC;

The issue of working weekends to deliver more care is complex and requires a thoughtful game plan to commit the resources for the value of the expanded services. In the times of COVID, the need for hospital throughput has never been more...

The issue of working weekends to...

03/02/2022

Cath Lab Digest

Original Contribution

Mid-Term Results of Everolimus-Eluting Stent in a Japanese Population Compared With a US Randomized Cohort: SPIRIT III Japan Registry With Harmonization by Doing

08/29/2012

Alexandra J. Lansky , MD;

Krishnankutty Sudhir , MD, PhD;

Takaaki Isshiki , MD;

Tadashi Kikuchi , MD, PhD;

Hiroshi Nonogi , MD, PhD;

Keiichi Igarashi , MD;

Kenshi Fujii , MD;

Kumiko Saito , MS, MPH;

Hiroshi Fujita , MD;

Shigeru Nakamura , MD;

Shigeru Saito , MD;

Kazuaki Mitsudo , MD;

Masato Nakamura , MD;

Takeshi Kimura , MD;

Hauro Hirayama , MD, PhD;

Gregg W. Stone , MD, FACC, FSCAI;

Yasuhiro Honda , MD;

Peter J. Fitzgerald , MD, PhD;

Katsuhisa Waseda , MD, PhD;

Abstract: To address safety concerns with first-generation drug-eluting stents (DESs), the everolimus-eluting stent (EES) has been developed as a second-generation DES. The study aim was to: (1) demonstrate that use of the EES in Japanese...

Abstract: To address safety...

08/29/2012

Journal of Invasive Cardiology